Matrix metalloproteinase-2 and -9 in the sera and in the urine of human oncocytoma and renal cell carcinoma

Di Carlo,Angelina

doi:10.3892/or.2012.1864

Matrix metalloproteinase-2 and -9 in the sera and in the urine of human oncocytoma and renal cell carcinoma

Authors:
- Angelina Di Carlo
View Affiliations

Affiliations: Department of Medico-Surgical Sciences and Biotechnologies, ‘Sapienza’ University of Rome, I-00161 Rome, Italy
Published online on: June 14, 2012 https://doi.org/10.3892/or.2012.1864
Pages: 1051-1056

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Matrix metalloproteinases (MMPs) are a family of zinc-dependent endopeptidases, capable of degrading all the molecular components of extracellular matrix. MMPs have been shown to play critical roles in tumor cell invasion and metastasis. We verified the activity of MMPs in the sera and in the urine of patients with kidney carcinoma by gelatin zymography. Of these patients, 16 had clear cell renal carcinoma (ccRCC) and 4 patients had oncocytoma. The sera and the urine of 16 healthy subjects were used as controls. In the sera, zymography analysis showed gelatinolytic bands at 72 kDa (gelatinase A) at 92, 130 and 240 kDa (gelatinase B). MMP-9 activity was slightly enhanced in sera from ccRCC compared with oncocytoma patients. Serum MMP-2 activity was similar in ccRCC and in oncocytoma patients. In the urine, 2 oncocytoma patients and 3 (33%) of the ccRCC patients showed gelatinolytic activity, whereas MMPs could not be detected in the concentrated urine of healthy subjects. The most abundant lytic activity was at 92 kDa, whereas MMP-2 was present in lesser quantities. However, there was broad overlap of the data and we did not find any correlation to type, stage or grade. Therefore, despite previous evidence, MMP-2 and -9 activity in serum and urine may not be useful biomarker for kidney carcinomas.

View Figures

View References

1	Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar
2	Cohen HT and McGoven FJ: Renal-cell carcinoma. N Engl J Med. 353:2477–2490. 2005. View Article : Google Scholar : PubMed/NCBI
3	Nagase H and Woessner JF: Matrix metalloproteinases. J Biol Chem. 274:21491–21494. 1999. View Article : Google Scholar
4	Egeblad M and Werb Z: New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2:161–174. 2002. View Article : Google Scholar : PubMed/NCBI
5	Björklund M and Koivunen E: Gelatinase-mediated migration and invasion of cancer cell. Biochim Biophys Acta. 1755:37–69. 2005.PubMed/NCBI
6	Sobin LH and Wittekind CH: International Union Against Cancer (UICC) TNM classification of malignant tumors. 6th edition. Wiley-Liss; New York, NY: pp. 193–195. 2002
7	Bradford MM: A rapid and sensitive method for quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 72:248–254. 1976. View Article : Google Scholar : PubMed/NCBI
8	Di Carlo A, Terracciano D, Mariano A and Macchia V: Urinary gelatinase activities (matrix metalloproteinase 2 and 9) in human bladder tumors. Oncol Rep. 15:1321–1326. 2006.PubMed/NCBI
9	Di Carlo A, Terracciano D, Mariano A and Macchia V: Matrix metalloproteinase-2 and matrix metalloproteinase-9 type IV collagenases in serum of patients with pleural effusions. Int J Oncol. 26:1363–1368. 2005.PubMed/NCBI
10	Triebel S, Bläser J, Reinke H and Tschesche H: A 25 kDa α₂-microglobulin-related protein is a component of the 125 kDa form of human gelatinase. FEBS Lett. 314:386–388. 1992.
11	Yan L, Borregaard N, Kjeldsen L and Moses MA: The high molecular weight urinary matrix metalloproteinase (MMP) activity is a complex of gelatinase B/MMP and neutrophil gelatinase-associated lipocalin (NGAL). J Biol Chem. 276:37258–37265. 2001. View Article : Google Scholar : PubMed/NCBI
12	Roy R, Louis GL, Loughlin KR, Wiederschain D, Kilroy SM, Lamb CC, Zurakowski D and Moses MA: Tumor-specific urinary matrix metalloproteinase fingerprinting: identification of high molecular weight urinary matrix metalloproteinase species. Clin Cancer Res. 14:6610–6617. 2008. View Article : Google Scholar
13	Goldberg GI, Strongin A, Collier IE, Genrich LT and Marmer BL: Interaction of 92-kDa type IV collagenase with the tissue inhibitor of metalloproteinases prevents dimerization, complex formation with interstitial collagenase, and activation of proenzyme with stromelysin. J Biol Chem. 267:4583–4591. 1992.
14	Russo P: Localized renal cell carcinoma. Curr Treat Options Oncol. 2:447–455. 2001. View Article : Google Scholar
15	Kashyap MK, Kumar A, Emelianenko N, Kaahyap A, Kaushik R, Huang R, Khullar M, Sharma SK, Singh SK, Bhargave AK and Upadhyava SK: Biochemical and molecular markers in renal cell carcinoma: an update and future prospects. Biomarkers. 10:258–294. 2005. View Article : Google Scholar : PubMed/NCBI
16	Struckmann K, Mertz K, Steu S, Storz M, Staller P, Krek W, Schraml P and Moch H: pVHL co-ordinately regulates CXCR4/CXCL12 and MMP2/MMP9 expression in human clear-cell renal cell carcinoma. J Pathol. 214:464–471. 2008. View Article : Google Scholar : PubMed/NCBI
17	Kallakury BV, Karikehalli S, Haholu A, Sheehan CE, Azumi N and Ross JS: Increased expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinases 1 and 2 correlate with poor prognostic variables in renal cell carcinoma. Clin Cancer Res. 7:3113–3119. 2001.PubMed/NCBI
18	Abdel-Wahed MM, Asaad NY and Aleskandarany M: Expression of matrix metalloproteinase-2 in renal cell carcinoma. J Egypt Nat Canc Inst. 16:168–177. 2004.PubMed/NCBI
19	Kugler A, Hemmerlein B, Thelen P, Kallerhoff M, Radzun HJ and Ringert RH: Expression of metalloproteinase 2 and 9 and their inhibitors in renal cell carcinoma. J Urol. 160:1914–1918. 1998. View Article : Google Scholar : PubMed/NCBI
20	Kamiya N, Kishimoto T, Suzuki H, Sekita N, Nagai Y, Oosumi N, Kito H, Tochigi N, Shinbo M, Nemori R, et al: increased in situ gelatinolytic activity in renal cell tumor tissues correlates with tumor size, grade and vessel invasion. Int J Cancer. 106:480–485. 2003. View Article : Google Scholar : PubMed/NCBI
21	Lein M, Jung K, Laube C, Hübner T, Winkelmann B, Stephan C, Hauptmann S, Rudolph B, Schnorr D and Loening SA: Matrix-metalloproteinases and their inhibitors in plasma and tumor tissue of patients with renal cell carcinoma. Int J Cancer. 85:801–804. 2000. View Article : Google Scholar : PubMed/NCBI
22	Cannon GM and Getzenberg RH: urinary matrix metalloproteinases activity is not significantly altered in patients with renal cell carcinoma. Urology. 67:848–850. 2006. View Article : Google Scholar : PubMed/NCBI
23	Sherief MH, Low SS, Miura M, Kudo N, Novick A and Weimbs T: Matrix metalloproteinase activity in urine of patients with renal cell carcinoma leads to degradation of extracellular matrix proteins: possible use as a screening assay. J Urol. 169:1530–1534. 2003. View Article : Google Scholar